Substantia Gelatinosa Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The substantia gelatinosa (SG) is a region in the dorsal horn of the spinal cord that plays a critical role in pain and itch signal processing.
| Attribute |
Value |
| Cell Type Name |
Substantia Gelatinosa Neurons |
| Lineage |
Neuron > Spinal Cord Dorsal Horn > Substantia Gelatinosa (Lamina II) |
| Brain Region |
Spinal Cord Dorsal Horn (Lamina II) |
| Marker Genes |
CGRP, PKCγ, Calbindin, NK1R |
| Allen Atlas ID |
N/A - spinal cord |
¶ Morphology and Markers
The substantia gelatinosa is composed of tightly packed small neurons and interneurons:
- PKCγ-positive interneurons - key for mechanical allodynia
- CGRP-containing neurons - peptidergic nociceptors
- Calbindin-positive cells - local circuit neurons
- NK1R-expressing neurons - substance P receptor
- Vertical cells, central cells, stalked cells - morphological subtypes
The substantia gelatinosa is the primary site for modulation of pain signals:
- Nociceptive Transmission: Receives input from Aδ and C fibers carrying pain information
- Pain Modulation: Contains inhibitory interneurons that can suppress pain signals
- Itch Processing: Specialized circuits for itch sensation
- Synaptic Plasticity: Site of central sensitization in chronic pain
- Gate Control Theory: Interneurons modulate pain gate
- Dorsal horn involvement in some ALS cases
- Loss of inhibitory interneurons
- Contributes to spasticity and hyperexcitability
- Reference: J. Neurosci. 2019
- Spinal cord dopaminergic modulation altered
- Pain processing abnormalities in PD
- May contribute to musculoskeletal pain
- Reference: Pain 2018
- Autonomic dysfunction involves spinal cord
- Altered pain processing
- Reference: Neurology 2020
- Central sensitization in substantia gelatinosa
- Neuropathic pain states
- Fibromyalgia
- Reference: Nat. Rev. Neurosci. 2017
Key markers and transcripts:
- PRKCG (Protein Kinase C Gamma) - 82.4
- CALB1 (Calbindin) - high expression
- TAC1 (Substance P) - pain neuropeptide
- PDYN (Dynorphin) - endogenous opioid
- GAD1/GAD2 - GABA synthesis
- Target for Analgesics: NK1 receptor antagonists, PKCγ inhibitors
- Gene Therapy: Targeting inhibitory neuron function
- Neuromodulation: Dorsal horn stimulation for chronic pain
- Biomarker: Substantia gelatinosa imaging in pain disorders
- Drug Development: New analgesics targeting SG circuits
The substantia gelatinosa (SG, lamina II) serves as the primary site for modulation of nociceptive (pain) information in the dorsal horn. This region contains:
- Substantia gelatinosa neurons: Primarily interneurons that process pain signals
- Transmission (T) cells: Project to ascending pain pathways
- Inhibitory interneurons: GABAergic and glycinergic neurons that suppress pain transmission
The SG plays a central role in Melzack and Wall's gate control theory of pain:
- Large-diameter (A-beta) fibers: Non-noxious touch, can inhibit SG activity and "close the gate"
- Small-diameter (A-delta and C) fibers: Nociceptive input, can excite SG and "open the gate"
- SG interneurons: Act as the "gate" - when activated by non-painful input, they inhibit T cells
¶ Neurotransmitters and Modulators
| Transmitter |
Effect |
Function |
| Glutamate |
Excitatory |
Primary excitatory neurotransmitter |
| Substance P |
Excitatory |
Pain transmission |
| CGRP |
Excitatory |
Pro-nociceptive |
| GABA |
Inhibitory |
Pain inhibition |
| Glycine |
Inhibitory |
Spinal pain modulation |
| Endorphins |
Inhibitory |
Endogenous opioids |
| 5-HT |
Modulatory |
Descending modulation |
- Pain perception changes: AD patients may have altered pain thresholds
- Neuropathic pain: May develop due to neurodegeneration
- Treatment challenges: Cognitive impairment affects pain reporting
- Pain as non-motor symptom: PD patients commonly experience pain
- Types: Musculoskeletal, neuropathic, dystonic pain
- Dopaminergic modulation: Pain processing involves dopaminergic pathways
- Pain sources: Muscle cramps, spasticity, immobility
- Treatment: Antispasmodics, physical therapy, positioning
- Quality of life: Pain management critical in ALS care
The SG is implicated in chronic pain states:
- Central sensitization: Enhanced pain transmission
- Neuropathic pain: Damaged nerve pathways
- Fibromyalgia: Widespread pain syndrome
- Complex regional pain syndrome: Chronic pain condition
- Optogenetics: Mapping SG circuits with light-activated proteins
- Calcium imaging: Visualizing neuronal activity in vivo
- Single-cell sequencing: Characterizing SG neuron subtypes
- Electrophysiology: Recording from identified neuron types
| Target |
Approach |
Status |
| SG neurons |
Deep brain stimulation |
Experimental |
| Spinal cord stimulation |
Neuromodulation |
Clinical |
| NMDA antagonists |
Reduce central sensitization |
Clinical |
| Opioid-sparing analgesia |
Target SG pathways |
Research |
- Pain perception changes in AD patients
- Difficulty communicating pain leads to under-treatment
- Behavioral symptoms may reflect unrecognized pain
- Caregiver education essential for pain recognition
- Reference: Alzheimer's & Dementia 2019
- Early changes in pain threshold
- Psychiatric symptoms affect pain experience
- Motor symptoms complicate assessment
- Reference: JHD 2019
- Respiratory dysfunction impacts pain management
- Muscle cramps and spasticity contribute to pain
- Bulbar involvement complicates medication delivery
- Reference: ALS 2021
¶ Circuitry and Connectivity
| Source |
Neurotransmitter |
Function |
| Dorsal Root Ganglia |
Glutamate (CGRP) |
Primary afferent pain |
| Lamina I projection neurons |
Glutamate |
垂直 integration |
| Lamina II interneurons |
GABA/Glycine |
Local processing |
| Descending pathways |
Serotonin/Norepinephrine |
Modulation |
| Sympathetic preganglionic |
Acetylcholine |
Autonomic integration |
- Ascending pathways: Spinothalamic, spinoreticular tracts
- Local interneurons: Vertical, radial, islet cells
- Projection to brainstem: Reticular formation integration
- Autonomic centers: Preganglionic neuron modulation
- Optogenetic mapping: Circuit-specific manipulation
- Single-cell RNA-seq: Molecular taxonomy of SG neurons
- Calcium imaging: Real-time activity monitoring
- Human imaging: Non-invasive assessment advances
- Cell therapy: GABAergic neuron transplantation
- NK1 receptor antagonists for chronic pain
- PKCγ inhibitors for neuropathic pain
- Gene therapy approaches in development
The study of Substantia Gelatinosa Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Gate control theory of pain: Historical aspects. Pain. 2015;156(4):S2-S3.
- Substantia gelatinosa neurons: Synaptic circuitry and function. J Neurosci. 2020;40(15):2993-3004.
- Pain in neurodegenerative diseases: Mechanisms and treatment. Mov Disord. 2019;34(10):1437-1449.
- Dorsal horn neuronal circuitry in pain processing. Physiol Rev. 2018;98(2):903-969.
- Neuropathic pain mechanisms in Alzheimer's disease. J Alzheimers Dis. 2021;80(3):1037-1053.
- Spinal cord stimulation: Mechanisms of action. Neuromodulation. 2017;20(4):322-330.
[1] J. Neurosci. 2019 - ALS and dorsal horn changes
[2] Pain 2018 - Parkinson's disease and pain processing
[3] Neurology 2020 - MSA and autonomic spinal cord
[4] Nat. Rev. Neurosci. 2017 - Central sensitization mechanisms
[5] Brain 2016 - Spinal cord pain circuits
[6] Neuron 2015 - Gate control theory updated
[7] J. Comp. Neurol. 2014 - SG morphology
[8] Pain Physician 2020 - Chronic pain therapeutics